Results 111 to 120 of about 35,256 (161)

Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy. [PDF]

Clin Cancer Res, 2017
Rogers LM, Mott SL, Smith BJ, Link BK, Sahin D, Weiner GJ.   +5 more
europepmc   +1 more source

The anti-CD20 monoclonal antibody rituximab to treat acquired haemophilia A. [PDF]

Blood Transfus, 2016
D'arena G, Grandone E, Di Minno MN, Musto P, Di Minno G.   +4 more
europepmc   +1 more source

Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus

Indian Journal of Dermatology, Venereology and Leprology, 2006
openaire   +2 more sources

Low risk of severe COVID-19 in vaccinated people with multiple sclerosis: a nationwide Norwegian study. [PDF]

BMJ Neurol Open
Rasmussen TH, Schikora-Rustad S, Lorentzen ÅR, Tran TT, Øverås MH, Myhr KM, Wergeland S, Aarseth J, Bø L, Berge T, Høgestøl EA, Harbo HF, Tveter AT, Jørgensen KK, Cunen C, Torkildsen Ø, Holmøy T, Celius EG, Vaage JT, Nygaard GO, Lund-Johansen F, König M.   +21 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Anti-CD20 monoclonal antibodies: Beyond B-cells

Blood Reviews, 2013
Anti-CD20 monoclonal antibodies (MoAbs), employed in treating CD20⁺ lymphomas and autoimmune diseases, appear to have broader functions than just eradicating malignant B-cells and decreasing autoantibody production. Rituximab-induced T-cell inactivation, reported both in-vitro and in-vivo, may contribute to the increased risk of T-cell-dependent ...
Irit, Avivi, Dina, Stroopinsky, Tamar, Katz   +2 more
openaire   +2 more sources

IRF8 regulates efficacy of therapeutic anti‐CD20 monoclonal antibodies

European Journal of Immunology, 2022
Abstract Anti‐CD20 monoclonal antibodies such as Rituximab, Ofatumumab, and Obinutuzumab are widely used to treat lymphomas and autoimmune diseases. They act by depleting B cells, mainly through Fc‐dependent effectors functions. Some patients develop resistance to treatment but the underlying mechanisms are poorly
Ludivine Grzelak, Ferdinand Roesch, Amaury Vaysse, Anne Biton, Rachel Legendre, Françoise Porrot, Pierre‐Henri Commère, Cyril Planchais, Hugo Mouquet, Marco Vignuzzi, Timothée Bruel, Olivier Schwartz   +11 more
openaire   +4 more sources

Anti-CD20 monoclonal antibodies in multiple sclerosis

Expert Review of Neurotherapeutics, 2016
The therapeutic utility of the anti-CD20 monoclonal antibodies (mAbs) is currently being evaluated in multiple sclerosis (MS) in line with the better understanding of the role of B lymphocytes in MS pathogenesis. Area covered: We conducted a literature search using Medline/Pub Med database of basic research and available controlled trials about anti ...
Irene, Moreno Torres, Antonio, García-Merino   +1 more
openaire   +2 more sources

Mechanisms of killing by anti-CD20 monoclonal antibodies

Molecular Immunology, 2007
CD20 is a cell-surface marker expressed on mature B cells and most malignant B cells, but not stem or plasma cells. It is an ideal target for monoclonal antibodies (mAb), such as rituximab and ofatumumab, as it is expressed at high levels on most B-cell malignancies, but does not become internalized or shed from the plasma membrane following mAb ...
Glennie, Martin J., French, Ruth R., Cragg, Mark S., Taylor, Ronald P.   +3 more
openaire   +3 more sources

Anti‐CD20 monoclonal antibody therapy in multiple myeloma

British Journal of Haematology, 2008
SummaryCD20 is a particularly appealing target that is expressed on the surface of almost all B cells, with no significant shedding, secretion or internalization. In contrast to the demonstrated efficacy of anti‐CD20 strategies in various B‐cell lymphoproliferative disorders, the role of such therapy in multiple myeloma is undetermined and ...
Prashant, Kapoor, Patricia T, Greipp, William G, Morice, S Vincent, Rajkumar, Thomas E, Witzig, Philip R, Greipp   +5 more
openaire   +2 more sources

Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia

Expert Opinion on Biological Therapy, 2012
The last decade has witnesd immense progress in the treatment of chronic lymphocytic leukemia (CLL). Chemoimmunotherapy (CIT) combining rituximab and fludarabine with cyclophosphamide (FCR) in the frontline setting has clearly been shown to improve outcomes in patients with CLL.
Preetesh, Jain, Susan, O'Brien
openaire   +2 more sources